Macrogenics (MGNX) Operating Income (2012 - 2026)

Macrogenics (MGNX) has reported Operating Income for 15 consecutive years, with -$33.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Income rose 21.55% year-over-year to -$33.4 million; the TTM figure through Mar 2026 stood at -$63.7 million (up 35.99% YoY), while the FY2025 annual figure was -$72.8 million, up 34.13% from the prior year.
• Operating Income eased to -$33.4 million in Q1 2026 per MGNX's latest filing, from -$12.1 million in the prior quarter.
• Across five years, Operating Income topped out at $54.2 million in Q3 2024 and bottomed at -$66.6 million in Q1 2022.
• Historically, Operating Income has averaged -$29.8 million across 5 years, with a median of -$38.4 million in 2023.
• Annual changes were most pronounced in 2023 — Operating Income plunged 511.87% — and 2024, when it soared 252.64%.
• Macrogenics' Operating Income stood at $12.0 million in 2022, then slumped by 511.87% to -$49.4 million in 2023, then slipped by 7.06% to -$52.8 million in 2024, then jumped by 77.11% to -$12.1 million in 2025, then slumped by 176.42% to -$33.4 million in 2026.
• Business Quant data shows MGNX's Operating Income at -$33.4 million in Q1 2026, -$12.1 million in Q4 2025, and $18.6 million in Q3 2025.